If our ongoing study shows similar results, this molecular profile, which was found in 30% of our patients, may identify a significant subset of NSCLC patients who derive minimal or no benefit from treatment with EGFR TKI. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.